A. Sarry

发表

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

M. Carroll, L. Linares, J. Portais, 2017, Cancer discovery.

Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy

M. Alvarez, C. Récher, C. Demur, 2014, Haematologica.

Impact of obesity in favorable‐risk AML patients receiving intensive chemotherapy

C. Récher, I. Luquet, E. Delabesse, 2016, American journal of hematology.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience

L. Créancier, A. Kruczynski, C. Récher, 2011, Oncotarget.

Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network

J. Laurent, C. Récher, O. Beyne-Rauzy, 2014, American journal of hematology.

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia

M. Carroll, J. Vial, C. Récher, 2022, Blood Cancer Journal.

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia

C. Récher, E. Forcade, N. Milpied, 2017, Oncotarget.

Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.

J. Vial, C. Récher, F. Despas, 2020, Blood advances.

Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors

C. Récher, I. Luquet, V. Mas, 2020, Leukemia & lymphoma.

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

J. Vial, C. Récher, I. Luquet, 2021, Blood Cancer Journal.

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

L. Fornecker, C. Récher, I. Luquet, 2020, PloS one.

Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study

C. Récher, I. Luquet, S. Dimicoli-Salazar, 2022, Leukemia & lymphoma.

Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.

C. Récher, M. Picard, E. Delabesse, 2018, Leukemia research.

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response

C. Mengelle, C. Récher, M. Attal, 2016, Medicine.

Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies

C. Récher, I. Luquet, Noémie Gadaud, 2018, Leukemia & lymphoma.

More than ten percent of relapses occur after five years in AML patients with NPM1 mutation

C. Récher, I. Luquet, E. Delabesse, 2020, Leukemia & lymphoma.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia

X. Thomas, C. Récher, E. Delabesse, 2018, European journal of haematology.

CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

C. Récher, I. Luquet, E. Delabesse, 2020, Cancers.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

G. Laurent, C. Récher, C. Demur, 2013, Blood.

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

C. Récher, I. Luquet, E. Delabesse, 2019, Cancer medicine.

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

J. Vial, C. Récher, I. Luquet, 2020, Cancers.

Genomic landscape of hyperleukocytic acute myeloid leukemia

C. Récher, I. Luquet, M. Picard, 2022, Blood cancer journal.

Improved outcome for AML patients over the years 2000–2014

G. Laurent, C. Récher, I. Luquet, 2017, Blood Cancer Journal.

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia

C. Récher, E. Forcade, N. Milpied, 2017, Oncotarget.

Dexamethasone in hyperleukocytic acute myeloid leukemia

M. Carroll, L. Linares, C. Récher, 2018, Haematologica.

Improved outcome for AML patients over the years 2000–2014

G. Laurent, C. Récher, I. Luquet, 2017, Blood Cancer Journal.

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

C. Delpierre, G. Laurent, C. Récher, 2019, BMC Cancer.

R. Bouabdallah, G. Laurent, C. Récher, 2016, Oncotarget.

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

M. Carroll, L. Linares, C. Récher, 2016 .

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

J. Vial, C. Récher, I. Luquet, 2020, Cancers.

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

M. Bernard, M. Béné, L. Fornecker, 2020, Leukemia.

Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.

C. Récher, I. Luquet, E. Delabesse, 2019, Leukemia research.

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

C. Delpierre, G. Laurent, C. Récher, 2019, BMC Cancer.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

G. Laurent, C. Récher, C. Demur, 2013, Blood.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience

L. Créancier, A. Kruczynski, C. Récher, 2011, Oncotarget.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

M. Carroll, L. Linares, J. Portais, 2017, Cancer discovery.

Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy

C. Récher, I. Luquet, A. Bidet, 2024, Cancer medicine.

Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.

I. Luquet, A. Bidet, J. Alliot, 2024, Leukemia research.

Vitamin C and D supplementation in acute myeloid leukemia

C. Récher, I. Luquet, Noémie Gadaud, 2023, Blood advances.